

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	4DMEDICAL LIMITED
ABN	31 161 684 831

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Andreas Fouras
Date of last notice	25 March 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	64,838,000 ordinary shares held by an entity Velocimetry Consulting Pty Ltd in which Andreas has more than 20% voting power. Thus Andreas is deemed to have the same relevant interest pursuant to section 608(3) of the Corporations Act 2001 as Velocimetry Consulting Pty Ltd in relation to the shares directly held by Velocimetry Consulting Pty Ltd.
Date of change	23 December 2022
No. of securities held prior to change	Direct 5,133,970 Fully Paid Ordinary Shares 6,738,412 Unlisted Options Indirect 64,838,000 Fully Paid Ordinary Shares
Class	Unlisted Options
Number acquired	1,850,914

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Grant of options with an exercise price of \$0.95 per Option calculated based on a 100% premium to the market value of Company shares equal to the 30-day volume weighted average price (VWAP) in the period immediately preceding 30 June 2026.
No. of securities held after change	Direct 5,133,970 Fully Paid Ordinary Shares 8,589,326 Unlisted Options exercisable at \$0.95, expiring on 30 June 2026 Indirect 64,838,000 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	The grant of 1,850,914 options to Managing Director and CEO, Dr Andreas Fouras was approved by the shareholders at the Annual General Meeting of 4DMedical Limited on 3 November 2022.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.